GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Revenue per Share

Apollon Formularies (AQSE:APOL) Revenue per Share : £0.00 (TTM As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Revenue per Share?

Apollon Formularies's revenue per share for the six months ended in Jun. 2023 was £0.00. Apollon Formularies's revenue per share for the trailing twelve months (TTM) ended in Jun. 2023 was £0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Apollon Formularies's Revenue per Share or its related term are showing as below:

AQSE:APOL's 3-Year Revenue Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.25
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Apollon Formularies Revenue per Share Historical Data

The historical data trend for Apollon Formularies's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Revenue per Share Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.14 - - -

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Apollon Formularies's Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollon Formularies's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's PS Ratio distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's PS Ratio falls into.



Apollon Formularies Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Apollon Formularies's Revenue Per Share for the fiscal year that ended in Dec. 2021 is calculated as

Revenue Per Share (A: Dec. 2021 )=Revenue (A: Dec. 2021 )/Shares Outstanding (Diluted Average) (A: Dec. 2021 )
=0.198/548.103
=0.00

Apollon Formularies's Revenue Per Share for the quarter that ended in Jun. 2023 is calculated as

Revenue Per Share (Q: Jun. 2023 )=Revenue (Q: Jun. 2023 )/Shares Outstanding (Diluted Average) (Q: Jun. 2023 )
=0.048/771.191
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollon Formularies  (AQSE:APOL) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Apollon Formularies Revenue per Share Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

6 Highly Predictable Companies with Historically Low P/S Ratios

By Dianne Tordillo Dianne Tordillo 11-27-2012

Apollo Education Group Is a Value Trap

By OPM Insights Nelson Hsu 10-15-2015

FPA Capital Fund Q1 2013 Commentary

By Holly LaFon Holly LaFon 04-24-2013

Yacktman Funds Comments on Apollo Group

By Holly LaFon Holly LaFon 03-13-2013

5 Stocks to Avoid - January 2017

By Benjamin Clark Benjamin Clark 01-14-2017

Weekly 3-Year Low Highlights: APOL, PDLI, TC, ALLT, ELRC

By Jimmy Xiao gurujx 05-17-2015

FPA Capital Fund Comments on For-Profit Education Stocks

By Holly LaFon Holly LaFon 12-09-2015

First Pacific Advisors Buys Alcoa, Bank of America

By Tiziano Frateschi Tiziano Frateschi 10-16-2015

5 Stocks Trading Near Their Historical Low P/S Ratios

By Holly LaFon Holly LaFon 04-11-2012

FPA Capital Comments on Apollo

By Holly LaFon 07-29-2013